Ferrara Napoleone 4
4 · Kalaris Therapeutics, Inc. · Filed Mar 18, 2025
Insider Transaction Report
Form 4
Ferrara Napoleone
Director
Transactions
- Award
Common Stock
2025-03-18+504,000→ 504,000 total
Footnotes (2)
- [F1]Shares issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the "Merger Agreement"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation ("KTx"), in exchange for outstanding shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the Merger).
- [F2]Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each share of KTx common stock was converted into and became exchangeable for the right to receive 0.2016 shares of common stock of the Issuer.